Q&A: FTC’s top healthcare enforcer on pharma M&A, company growth and PBMs
The Federal Trade Commission has loomed large over M&A in the biopharma industry in the last two years. The antitrust regulator attempted to block Amgen’s $27.8 billion takeover of Horizon, stopped...
View ArticleClik here to view.
FDA rejects liver cancer drug combo, shares of Korean biotech tank
Korean biotech HLB and its China-based partner Jiangsu Hengrui Pharmaceuticals said Friday that the FDA rejected their drug combination for the most common form of liver cancer. The FDA rejected the...
View ArticleEMA's safety committee recommends suspending preterm birth drugs
The European Medicines Agency is taking aim at preterm birth drugs, with the agency’s safety committee recommending that medicines containing 17-hydroxyprogesterone caproate, also known as 17-OHPC, be...
View ArticleModerna scores European victory over Pfizer and BioNTech in mRNA patent battle
The European Patent Office on Thursday handed a win to Moderna in a long-running patent battle with Pfizer and BioNTech over certain components of the mRNA vaccines authorized to fight Covid-19. “We...
View ArticleClik here to view.
Study identifies groups of people who mistrust the FDA
The FDA has work to do to earn the confidence of certain groups of people who do not trust the agency, a study published Friday by researchers at Harvard Medical School and the University of Colorado...
View ArticleClik here to view.
Rapport, a clinical-stage neuroscience biotech, files for IPO
Rapport Therapeutics, which emerged out of Johnson & Johnson’s neuroscience unit last year, has submitted its pitch for a Nasdaq listing. The Boston-based startup plans to trade as “RAPP” and...
View ArticleMega startup watch; Interview with Siddhartha Mukherjee; Tracking Wegovy’s...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleFDA withdraws Helsinn’s accelerated approval for cancer drug after company’s...
The FDA on Friday withdrew an accelerated approval for Helsinn’s bile duct cancer drug, two years after the company couldn’t complete its confirmatory trial and requested that the FDA withdraw...
View ArticleLabGenius raises £35M to develop solid tumor drugs based on machine learning
LabGenius has secured £35 million ($44.5 million) in a Series B raise to expand its antibody discovery platform and advance a pipeline of cancer candidates. The UK biotech will use the same machine...
View ArticleGSK says long-acting asthma treatment depemokimab clears two Phase 3 studies
GSK announced Tuesday morning that its experimental antibody treatment reduced the yearly rate of asthma attacks across two key clinical trials for adolescents and adults with a form of severe asthma....
View ArticleADC biotech Pheon raises $120M to test three assets in the clinic
Investors continue to flock toward antibody-drug conjugates. Pheon Therapeutics is the latest to catch the tailwinds of the booming segment of oncology R&D. The London-based startup disclosed a...
View ArticleClik here to view.
AstraZeneca targets $80B revenue, 20 new drugs by 2030
AstraZeneca on Tuesday morning unveiled its ambitious plan to be one of the fastest growing pharma companies by the end of the decade. In what CEO Pascal Soriot described as “a new era of growth,” the...
View ArticleClik here to view.
FDA lifts partial clinical hold on Larimar’s Friedreich’s ataxia treatment
Larimar Therapeutics’ stock $LRMR shot up by as much as 20% after announcing Monday that the FDA had lifted its partial clinical hold on its treatment for Friedreich’s ataxia, a rare disorder that...
View ArticleClik here to view.
Lilly makes another radiopharma move in collaboration with Aktis Oncology
Eli Lilly is again dipping into the buzzy area of radiopharmaceuticals by way of private biotech Aktis Oncology. The pharma giant will dish out $60 million upfront and make an undisclosed equity...
View ArticleAltruBio secures $225M for an updated version of its ulcerative colitis drug
Bay Area and Taipei biotech AltruBio has raised $225 million in a Series B to move forward its experimental drug for ulcerative colitis and other chronic autoimmune conditions, it said Tuesday. The...
View ArticleAI biotech Exscientia to trim nearly a quarter of workforce, following...
Exscientia announced a $40 million cost-saving program on Tuesday that will lead to layoffs affecting 20% to 25% of the company’s workers. The move, disclosed as part of a first-quarter update Tuesday...
View ArticleClik here to view.
Sanofi, OpenAI, Formation Bio announce AI drug development partnership
French pharmaceutical giant Sanofi will work with the tech powerhouse OpenAI and New York-based startup Formation Bio to develop AI-powered software in drug R&D, the three companies announced...
View ArticleClik here to view.
With a fresh $100M, Monte Rosa CEO details plans to move several molecular...
Monte Rosa Therapeutics CEO Markus Warmuth expects molecular glues to make up a new class of drugs with “almost unlimited potential” in the long run, allowing scientists to tackle disease-causing...
View ArticleLyra to lay off 75% of its workers; Dupixent nears COPD decision
Plus, news about BioNTech, Medigene, YGION Biomedical, Eli Lilly and Alloy Therapeutics: Lyra lays off 87 employees: The Watertown, MA-based biotech will let go of 75% of its workforce, stop...
View ArticleAstraZeneca outlines growth plans for 2030 and beyond with focus on...
CAMBRIDGE, UK — Pascal Soriot has set an ambitious $80 billion revenue target for AstraZeneca by 2030. But he’s not stopping there. At the drugmaker’s Discovery Centre in Cambridge, UK, the CEO,...
View Article